Current face of acute otitis media: Microbiology and prevalence resulting from widespread use of heptavalent pneumococcal conjugate vaccine

Clinical Therapeutics

Volumn 28, Issue 1, 2006, Pages 118-123

  Brunton, Stephen ^a  

^a AMERICAN ACADEMY OF FAMILY PHYSICIANS   (United States)

Author keywords

Acute otitis media; AOM; H infuenzae; Haemopbilus infuenzae; Heptavalent pneumococcal conjugate vaccine; Microbiology; PCV 7; S pneumoniae; Streptococcus pneumoniae

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFDINIR; PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; CLINICAL TRIAL; DRUG RELEASE; HUMAN; MEDLINE; MORAXELLA CATARRHALIS; PREVALENCE; RECURRENT DISEASE; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 32844455488     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.01.011     Document Type: Article

References (29)

1. Physicians' Desk Reference® [CD-ROM] 2005 Thomson Micromedex Greenwood Village, Colo
2. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: Recommendations of the advisorycommittee on immunization practices (ACIP) MMWR Morb Mortal Wkly Rep. 49 2000 1 38
3. Dagan R., Givon-Lavi N., and Shkolnik L. Acute otitis media caused by antibiotic-resistant Streptococcus pneumoniae in southern Israel: Implication for immunizing with conjugate vaccines J Infect Dis 181 2000 1322 1329
4. Joloba M.L., Windau A., and Bajaksouzian S. Pneumococcal conjugate vaccine serotypes of Streptococcus pneumoniae isolates and the antimicrobial susceptibility of such isolates in childrenwith otitis media Clin Infect Dis 33 2001 1489 1494
5. Block S.L., Hedrick J., and Harrison C.J. Pneumococcal serotypes from acute otitis media in rural Kentucky Pediatr Infect Dis J 21 2002 859 865
6. Wald E.R., Mason E.O. Jr, Bradley J.S. US Pediatric Multicenter Pneumococcal Surveillance Group Acute otitis media caused by Streptococcus pneumoniae in children's hospitals between 1994 and 1997 Pediatr Infect Dis J 20 2001 34 39
7. Updated recommendations on the use of pneumococcal conjugate vaccine: Suspension of recommendation for third and fourth dose MMWR Morb Mortal Wkly Rep 53 2004 177 178
8. National, state, and urban area vaccination coverage among children aged 19-35 months-United States, 2004 MMWR Morb Mortal Wkly Rep 54 2005 717 721
9. Block S.L., Hedrick J., and Harrison C.J. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media Pediatr Infect Dis J 23 2004 829 833
10. Casey J.R., and Pichichero M.E. Changes in frequency and pathogens causing acute otitis media in 1995-2003 Pediatr Infect Dis J 23 2004 824 828
11. Eskola J., Kilpi T., Palmu A. Finnish Otitis Media Study Group Efficacy of a pneumococcal conjugate vaccine against acute otitis media N Engl J Med. 344 2001 403 409
12. Black S., Shinefield H., Fireman B. Northern California Kaiser Permanente Vaccine Study Center Group Efficacy, safety and immunogenicity of heptava lent pneumococcal conjugate vaccine in children Pediatr Infect Dis J 19 2000 187 195
13. [published correction appears in Pediatr Infect Dis J. 2003;22:163] Fireman B., Black S.B., and Shinefield H.R. Impact of the pneumococcal conjugate vaccine on otitis media Pediatr Infect Dis J 22 2003 10 16
14. (Suppl) Block S.L., Hedrick J.A., and Harrison C.J. Widespread use of conjugated pneumococcal vaccine significantly reduces rates of AOM and antibiotic usage Abstract 1135 Pediatr Res 55 2004 201A
15. Poehling K.A., Lafleur B.J., and Szilagyi P.G. Population-based impact of pneumococcal conjugate vaccine in young children Pediatrics 114 2004 755 761
16. Harrison C.J., Marks M.I., and Welch D.F. Microbiology of recently treated acute otitis media compared with previously untreated acute otitis media Pediatr Infect Dis 4 1985 641 646
17. Pichichero M.E. Evolving shifts in otitis media pathogens: Relevance to a managed care organization Am J Manag Care 11 Suppl 6 2005 5192 5201
18. Block S.L., Harrison C.J., and Hedrick J.A. Penicillin-resistant Streptococcus pneumoniae in acute otitis media: Risk factors, susceptibility patterns and antimicrobial management Pediatr Infect Dis J. 14 1995 751 759
19. McEllistrem M.C., Adams J., Mason E.O., and Wald E.R. Epidemiology of acute otitis media caused byStrepto coccus pneumoniae before and after licensure of the 7-valent pneumococcal protein conjugatevaccine J Infect Dis. 188 2003 1679 1684
20. Kilpi T., Ahman H., Jokinen J. Finnish Otitis Media Study Group Protective efficacy of a sec ond pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: Randomized, controlled trial of a 7valent pneumococcal polysaccharidemeningococcal outer membrane protein complex conjugate vaccine in 1666 children Clin Infect Dis 37 2003 1155 1164
21. Jorgensen J.H., Doern G.V., and Maher L.A. Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States Antimicrob Agents Chemother 34 1990 2075 2080
22. Jacobs M.R., Bajaksouzian S., and Zilles A. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997U.S. Surveillance study Antimicrob Agents Chemother 43 1999 1901 1908
23. Pelton S.I., and Klein J.O. The promise of immunoprophylaxis for prevention of acute otitis media Pediatr Infect Dis J 18 1999 926 935
24. Black S., Shinefield H., and Baxter R. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente Pediatr Infect Dis J 23 2004 485 489
25. Whitney C.G., Farley M.M., and Hadler J. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction ofprotein-polysaccharide conjugate vaccine N Engl J Med 348 2003 1737 1746
26. Block S.L., Busman T.A., Paris M.M., and Bukofzer S. Comparison of five-day cefdinir treatment with ten-day low dose amoxicillin/clavulanate treatment for acute otitis media Pediatr Infect Dis J 23 2004 834 838
27. Jacobs M.R., Bajaksouzian S., and Windau A. Susceptibility of Streptococcus pneumoniae, Haemophilus in fluenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based onpharmacodynamic parameters: 1998-2001 US Surveillance Study Clin Lab Med 24 2004 503 530
28. Jacobs M.R. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters Clin Microbiol Infect 7 2001 589 596
29. American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media Diagnosis and management of acute otitis media Pediatrics 113 2004 1451 1465